Clinical trials: Oral Anticoagulants
Ischemic Stroke, Intracerebral Hemorrhage
Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime
The Registry of Acute Stroke Under Novel Oral Anticoagulants-Prime (RASUNOA-Prime), an investigator-initiated study, is a German multicenter, prospective, observational registry.
- Conditions
- Ischemic Stroke, Intracerebral Hemorrhage, Oral Anticoagulation, Cardiovascular Diseases
- Trial name
- RASUNOA-Prime (NCT02533960)
- Testing
- not applicable (observational study)
- Where
- Germany
- Volunteers
- 3,832 people
- Sponsor
- University Hospital Heidelberg
Deep Vein Thrombosis
Absence of Residual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants
Background. The optimal duration of oral anticoagulant treatment in patients with idiopathic Deep Vein Thrombosis (DVT)of the lower limbs is still uncertain.
- Trial name
- Exten-DACUS (NCT00623987)
- Testing
- warfarin accordingly INR value
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
Atrial Fibrillation, Stroke
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs.
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- NEW-AF (NCT03702582)
- Testing
- Rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Acute Ischemic Stroke
Intravenous Thrombolysis and NOAC
New oral anticoagulants (NOACs), including rivaroxaban, apixaban, dabigatran, and edoxaban, have become the first-line therapy for preventing ischemic stroke associated with non-valvular atrial fibrillation (NVAF).
- Trial name
- NCT06749834
- Testing
- Intravenous thrombolysis
- Where
- 2 sites in China
- Volunteers
- 280 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hemorrhage, Thrombosis
Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department
Rationale: According to the latest National Survey on Care-Related Adverse Events, anticoagulants, including vitamin K antagonists (VKAs), rank first among medications responsible for serious iatrogenic accidents (37% in 2004…
- Conditions
- Hemorrhage, Thrombosis, Anticoagulant Therapy, Traumatic Hemorrhage
- Trial name
- ADEOA (NCT06692504)
- Where
- France
- Volunteers
- 2,080 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Atrial Fibrillation
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
A prospective non-interventional single-centre study aimed to evaluate actual adherence of AF patients using the validated adherence Scale.
- Trial name
- ANTEY (NCT03790917)
- Where
- Russia
- Volunteers
- 201 people
- Sponsor
- National Research Center for Preventive Medicine
Tooth Extraction
Tranexamic Acid To Reduce Bleeding in Patients Treated With New Oral Anticoagulants Undergoing Dental Extraction
In patients treated with direct oral anticoagulants, bleeding events during or after tooth extraction can lead to unscheduled interruption of the antithrombotic treatment and a potential increased risk of thrombo-embolic events.
- Trial name
- EXTRACT-NOAC (NCT03413891)
- Testing
- Tranexamic Acid
- Where
- Belgium
- Volunteers
- 222 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Chronic Subdural Hematoma, Atrial Fibrillation (AF)
Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation
The goal of this randomized clinical trial is to assess the benefit of early resumption versus late resumption of oral anticoagulation medication in adults with atrial fibrillation undergoing surgery for chronic subdural…
- Trial name
- RELACS (NCT06696079)
- Testing
- Early Resumption of Oral Anticoagulation Therapy, Late Resumption of Oral Anticoagulation Therapy
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 332 people
- Sponsor
- Rahul Raj
Ischemic Stroke, Intracranial Hemorrhages
Novel Oral Anticoagulants in Stroke Patients
The present study will monitor and explore acute neurovascular emergencies in patients treated with NOACs compared to those under treatment with VKAs.
- Trial name
- NOACISP (NCT02353585)
- Where
- Switzerland
- Volunteers
- 1,050 people
- Sponsor
- University Hospital, Basel, Switzerland
Ischemic Stroke, Oral Anticoagulation
Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or…
- Conditions
- Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment
- Trial name
- ASPERA (NCT06823466)
- Where
- 47 sites in Croatia, Denmark and 13 more
- Volunteers
- 200 people
- Sponsor
- University of L'Aquila
Pulmonary Embolism, Intermediate-high Risk
Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism
Pilot randomized study of the sidlenafil efficacy in combination with oral anticoagulants in the treatment of patients with intermediate-high risk of pulmonary embolism
- Conditions
- Pulmonary Embolism, Intermediate-high Risk, Combination of Oral Anticoagulation Therapy and Sildenafil
- Trial name
- PSCAT (NCT02946944)
- Testing
- Sildenafil/apixaban, apixaban
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Deep Vein Thrombosis, Superficial Thrombophlebitis
DOACT Algorithm Versus AI-Based Decision Models in Oral Anticoagulant Therapy for Vascular Patients
Study using a decision algorithm for the application of an oral anticoagulant calculator in vascular diseases, aimed at validating a clinical decision-support tool for conditions such as deep vein thrombosis, superficial…
- Conditions
- Deep Vein Thrombosis, Superficial Thrombophlebitis, Pulmonary Thromboembolisms, Clinical Decision Support Systems
- Trial name
- DOACT (NCT07290608)
- Testing
- DOACT algorithm, No algorithm, LLM-based tools
- Where
- Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- ITALO EUGENIO SOUZA GADELHA DE ABREU
Knowledge, Attitudes, Practice
Learning Theory Patient Education for Anticoagulants
The goal of this study is to test the feasibility of a randomized control trial evaluating the educational tool for anticoagulated patients.
- Trial name
- NCT06138184
- Testing
- Anticoagulation Educational Materials, Control Group: Standard of Care
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Utah
Atrial Fibrillation
Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Pilot
The proposed PAUSE-2 RCT study is the logical next step to the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study, which was completed on August 31, 2018.
- Trial name
- PAUSE2rctP (NCT04192552)
- Testing
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Where
- 3 sites in Canada
- Volunteers
- 201 people
- Sponsor
- McMaster University
Coronary Artery Disease, Bleeding
Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures
Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present with concomitant ischemic heart disease and often require coronary angiography with or without percutaneous coronary intervention (PCI).
- Conditions
- Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction
- Trial name
- DOAC-NOSTOP (NCT05292846)
- Testing
- Direct-acting oral anticoagulation
- Where
- 4 sites in Italy, Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Universitario La Fe
Bleeding
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
The purpose of this study was to evaluate the hemostatic efficacy of andexanet alfa (andexanet) in participants receiving a factor Xa (FXa) inhibitor (apixaban, rivaroxaban, edoxaban, enoxaparin) who were experiencing an acute…
- Trial name
- NCT02329327
- Testing
- Andexanet
- Where
- 87 sites in United States, Belgium and 7 more
- Volunteers
- 479 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Gastrointestinal Bleeding, Cardiovascular Complication
Gastrointestinal Endoscopy in Patients With Prothrombotic Conditions: THE ENDOHEM REGISTRY
This observational study evaluates the safety of gastrointestinal endoscopy in patients on oral anticoagulants (Vitamin K antagonists, rivaroxaban, dabigatran, edoxaban, and apixaban).
- Conditions
- Gastrointestinal Bleeding, Cardiovascular Complication, Anticoagulants; Circulating, Hemorrhagic Disorder, Gastrointestinal Endoscopy
- Trial name
- NCT03669068
- Testing
- Gastrointestinal endoscopy
- Where
- Spain
- Volunteers
- 1,602 people
- Sponsor
- Hospital Universitario Ramon y Cajal
Stroke
Study of the Follow-up of Stroke Treated With Anticoagulants
Stroke is a major public health problem as it is very frequent (140,000 cases/year in France), and very serious (leading cause of death, 2nd leading cause of dementia, 3rd leading cause of handicap).
- Trial name
- AOD (NCT03292575)
- Testing
- Anticoagulants
- Where
- France
- Volunteers
- 441 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Acute Coronary Syndrome, Atrial Fibrillation
APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF
It is hypothesised that a dual therapy strategy by oral anticoagulation with the new Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with phenprocoumon plus acetylsalicylic acid (ASA) and…
- Conditions
- Acute Coronary Syndrome, Atrial Fibrillation, Coronary Artery Disease
- Trial name
- APPROACH (NCT02789917)
- Testing
- Dual Therapy, Triple Therapy
- Where
- 16 sites in Germany
- Volunteers
- 403 people
- Sponsor
- LMU Klinikum
Coagulation
Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™
The Perosphere ClotChek™ system consists of a hand-held, battery-operated blood coagulation instrument and disposable test cuvettes for use at the point-of-care (POC).
- Trial name
- NCT07012291
- Testing
- Whole Blood Clotting Time
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- Perosphere Technologies Inc.